SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment

BACKGROUND: SHON nuclear expression (SHON-Nuc(+)) was previously reported to predict clinical outcomes to tamoxifen therapy in ERα(+) breast cancer (BC). Herein we determined if SHON expression detected by specific monoclonal antibodies could provide a more accurate prediction and serve as a biomark...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdel-Fatah, Tarek M. A., Broom, Reuben J., Lu, Jun, Moseley, Paul M., Huang, Baiqu, Li, Lili, Liu, Suling, Chen, Longxin, Ma, Runlin Z., Cao, Wenming, Wang, Xiaojia, Li, Yan, Perry, Jo K., Aleskandarany, Mohammed, Nolan, Christopher C., Rakha, Emad A., Lobie, Peter E., Chan, Stephen Y. T., Ellis, Ian O., Hwang, Le-Ann, Lane, David P., Green, Andrew R., Liu, Dong-Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461947/
https://www.ncbi.nlm.nih.gov/pubmed/30816325
http://dx.doi.org/10.1038/s41416-019-0405-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461947/
https://www.ncbi.nlm.nih.gov/pubmed/30816325
http://dx.doi.org/10.1038/s41416-019-0405-x

Ejemplares similares